Results

1–10 of 196 results for Intravitreal

Rates of Post Intravitreal Anti-VEGF Injection Endophthalmitis: Management Strategies and Visual Acuity Outcomes From the AAO IRIS Registry
Alia K Durrani, MD
Annual Meeting Talks
2023
Prospective Imaging of the Intravitreal Fluocinolone Acetonide Implant Using Fluorescein Angiography and OCT in Uveitis (PANTHER)
Sunil Srivastava, MD
Annual Meeting Talks
2023
Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy Associated with Rhegmatogenous Retinal Detachment: The Phase II FIXER Trial
Ayman Elnahry, MD, PhD
Annual Meeting Talks
2023
Naive SubRetinal Hemorrhage in Neovascular AMD—Pneumatic Displacement, Subretinal Air, and tPA: Subretinal vs Intravitreal Aflibercept: The NATIVE Study
Matias Iglicki, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Systemic Adverse Events in Patients With Diabetes Treated With Intravitreal Antivascular Endothelial Growth Factor Injections
Roomasa Channa, MD
Annual Meeting Talks
2023
Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023
Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration
Keyvan Koushan, MD, FRCSC
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis
David T.W. Wong, MD, FRCS(C), FASRS
Annual Meeting Talks
2023
Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis
David R. Chow, MD, FRCS(C)
Annual Meeting Talks
2023